1Macintyre L, Capewell S, Stewart S, et al. Evidence of umproving propnosis in heart failure : trends in case fatality in 66547 patients hospitalized between 1986 and 1995[J].Circulation,2000,102, 1126-1131.
2ACC/AHA Task Force Report.Guideline for the evaluation and management of heart failure[J].JACC, 1995,26:1376-1398.
3Sabhah HN, Goldstein S. Ventricular remodeling consenquences and therapy[J].Eur Heart J,1993, 14(SUPPL C):24-29.
4ACC/AHA Guidelines for the evaluation and management of chronic heart failure[J].Circulation,2001,104:2996-3007.
5Reisin C, Schneeweiss A. Spontaneous disappearance of cough induced by angiotensin converting enzyme inhibitors ( captopril or enalapril) [J].Am J Cardiol, 1992, 70:398-399.
6Mazzola C, Bumier MR .Comparative safety and tolerahility of angiotensin II receptor antagoaists[J].Drug ,1999, 21:23-33.
7Cohn JN, Toghoni GA.Randomized trial of the angiotersin-receptor block valsartan chronic heart failure[J].N Engl : Med ,2001, 345(23):1667-1675.
8Pfeffer MA. Swedberg K Granger CB. et al . Effects of candesaetan on mcrtality and morbidity in patients with chronic heart failure : the CHARM-OVERALL programme[J].Lancet,2003,362:759-766.
9Birstow MR. Mechanism of action of betablocking agents in heart failure[J].Am J Cardiol,1997,80:26-40.
10Birstow MR.β-adrenergic receptor blockade in chronic failure[J].Circulation,2000,101:558-569.
